Cargando…

Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)

OBJECTIVES: To compare the rate disparity between outcomes (overall survival (OS), progression-free survival (PFS), and safety) of concurrent chemoradiation (cCRT) followed by durvalumab in two patient cohorts with locally advanced (LA) stage III non-small cell lung cancer (NSCLC), one non-Hispanic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raez, Luis E., Arrieta, Oscar, Chamorro, Diego F., Soberanis-Piña, Pamela Denisse, Corrales, Luis, Martín, Claudio, Cuello, Mauricio, Samtani, Suraj, Recondo, Gonzalo, Mas, Luis, Zatarain-Barrón, Zyanya Lucia, Ruíz-Patiño, Alejandro, García-Robledo, Juan Esteban, Ordoñez-Reyes, Camila, Jaller, Elvira, Dickson, Franco, Rojas, Leonardo, Rolfo, Christian, Rosell, Rafael, Cardona, Andrés F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321635/ https://www.ncbi.nlm.nih.gov/pubmed/35903685 http://dx.doi.org/10.3389/fonc.2022.904800

Ejemplares similares

Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP)
por: Cardona, Andrés F., et al.
Publicado: (2020)

Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non‐small cell lung cancer (AB‐CLICaP)
por: Ruiz‐Patiño, Alejandro, et al.
Publicado: (2020)

Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
por: Rojas, Leonardo, et al.
Publicado: (2019)

Characteristics and outcomes of thymomas in Latin America: Results from over 10 years of experience (CLICaP‐LATimus)
por: Martín, Claudio, et al.
Publicado: (2021)

Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
por: Ruiz‐Patiño, Alejandro, et al.
Publicado: (2019)

Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP)
por: Cardona, Andrés F., et al.
Publicado: (2019)

Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study
por: Chamorro, Diego F., et al.
Publicado: (2023)

Mortality and Advanced Support Requirement for Patients With Cancer With COVID-19: A Mathematical Dynamic Model for Latin America
por: Ruiz-Patiño, Alejandro, et al.
Publicado: (2020)

When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review
por: Rodríguez, July, et al.
Publicado: (2021)

Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries
por: Cardona, Andrés F., et al.
Publicado: (2020)

KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
por: Garcia-Robledo, Juan Esteban, et al.
Publicado: (2022)

Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
por: Cardona, Andrés F., et al.
Publicado: (2021)

p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics
por: Ruiz-Patiño, Alejandro, et al.
Publicado: (2021)

Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID‐19 pandemic: the THOCOoP cooperative group
por: Arrieta, Oscar, et al.
Publicado: (2020)

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
por: Shaverdian, Narek, et al.
Publicado: (2020)

Chronic and Severe Non-Lichenoid Oral Ulcers Induced by Nivolumab − Diagnostic and Therapeutic Challenge: A Case Report
por: Cardona, Andrés F., et al.
Publicado: (2020)

Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies
por: Sotelo-Rodríguez, Diana Carolina, et al.
Publicado: (2019)

Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib
por: Corrales, Luis, et al.
Publicado: (2017)

Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
por: Lau, Sally C.M., et al.
Publicado: (2021)

Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer
por: Hassanzadeh, Comron, et al.
Publicado: (2020)

Sarcoid-Like Granulomatosis of the Lung Related to Durvalumab After Chemoradiation for Pulmonary Squamous Cell Carcinoma
por: Minami, Seigo, et al.
Publicado: (2023)

Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
por: Langberg, Christian Wilhelm, et al.
Publicado: (2023)

Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer
por: Soberanis Pina, Pamela, et al.
Publicado: (2023)

Comprehensive review of fetal adenocarcinoma of the lung
por: Ricaurte, Luisa María, et al.
Publicado: (2018)

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
por: Ordóñez-Reyes, Camila, et al.
Publicado: (2022)

Phimosis: A rare complication of immunotherapy with durvalumab
por: Vázquez-Lavista, Luis Gabriel, et al.
Publicado: (2020)

Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report
por: Moodie, Travis, et al.
Publicado: (2022)

Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
por: Preti, Beatrice T. B., et al.
Publicado: (2023)

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
por: Alessi, Joao V., et al.
Publicado: (2023)

Atypical Skin Manifestations During Immune Checkpoint Blockage in Coronavirus Disease 2019–Infected Patients With Lung Cancer
por: Rolfo, Christian, et al.
Publicado: (2020)

Neuregulin 1 Gene (NRG1). A Potentially New Targetable Alteration for the Treatment of Lung Cancer
por: Rosas, Daniel, et al.
Publicado: (2021)

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2023)

Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real‐world comparison of treatment outcomes to historical controls treated with chemoradiation alone
por: Saad, Akram, et al.
Publicado: (2022)

Durvalumab in NSCLC: latest evidence and clinical potential
por: Muñoz-Unceta, Nerea, et al.
Publicado: (2018)

BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations
por: Cardona, Andrés F., et al.
Publicado: (2016)

Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
por: Thungappa, Satheesh, et al.
Publicado: (2017)

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer
por: Chu, Chia‐Hsun, et al.
Publicado: (2020)

Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
por: Jazieh, Khalid, et al.
Publicado: (2022)

Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab
por: Diamond, Brett H., et al.
Publicado: (2022)

Case Report: Differential Genomics and Evolution of a Meningeal Melanoma Treated With Ipilimumab and Nivolumab
por: Burgos, Remberto, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ok0j3ntk0pon8qt17tqf08ptkf